Literature DB >> 21848699

Hemojuvelin hemochromatosis receiving iron chelation therapy with deferasirox: improvement of liver disease activity, cardiac and hematological function.

Takashi Maeda, Tsuyoshi Nakamaki, Bungo Saito, Hidetoshi Nakashima, Hirotsugu Ariizumi, Kouji Yanagisawa, Ai Hattori, Yasuaki Tatsumi, Hisao Hayashi, Kenshi Suzuki, Shigeru Tomoyasu.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2011        PMID： 21848699     DOI： 10.1111/j.1600-0609.2011.01693.x

Source DB:  PubMed          Journal:  Eur J Haematol        ISSN： 0902-4441            Impact factor:   2.997


× No keyword cloud information.
  4 in total

Review 1.  Genotypic and phenotypic spectra of hemojuvelin mutations in primary hemochromatosis patients: a systematic review.

Authors:  Xiaomu Kong; Lingding Xie; Haiqing Zhu; Lulu Song; Xiaoyan Xing; Wenying Yang; Xiaoping Chen
Journal:  Orphanet J Rare Dis       Date:  2019-07-08       Impact factor: 4.123

2.  Juvenile Hemochromatosis due to a Homozygous Variant in the HJV Gene.

Authors:  María-Belén Moreno-Risco; Manuel Méndez; María-Isabel Moreno-Carralero; Ana-María López-Moreno; José-Manuel Vagace-Valero; María-José Morán-Jiménez
Journal:  Case Rep Pediatr       Date:  2022-04-11

3.  A late presentation of a fatal disease: juvenile hemochromatosis.

Authors:  Cynthia Cherfane; Pauline Lee; Leana Guerin; Kyle Brown
Journal:  Case Rep Med       Date:  2013-09-11

4.  Reversal of end-stage heart failure in juvenile hemochromatosis with iron chelation therapy: a case report.

Authors:  Shamil D Cooray; Neel M Heerasing; Laura A Selkrig; V Nathan Subramaniam; P Shane Hamblin; Cameron J McDonald; Catriona A McLean; Elissa McNamara; Angeline S Leet; Stuart K Roberts
Journal:  J Med Case Rep       Date:  2018-01-26
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.